Comedian Aishwarya Mohanraj shared her six-month weight loss journey in a new video.
She revealed using Mounjaro, a prescription GLP-1 based medication, under medical supervision.
Her story has renewed interest in tirzepatide and GLP-1 weight loss injections in India.
Stand-up comedian and content creator Aishwarya Mohanraj has publicly shared details of her weight loss journey in a YouTube video released on February 6, 2026, explaining how she reduced her body weight by approximately 20 kilograms over six months with the help of a prescription medication called Mounjaro (tirzepatide).
Tirzepatide is a dual GIP and GLP-1 receptor agonist approved in several countries for type 2 diabetes and chronic weight management. Clinical outcomes vary widely between individuals, depending on baseline weight, metabolic health, and adherence to medical guidance.
In the video, Mohanraj said her weight decreased from around 74 kg to approximately 52 kg after six months of weekly injections. She clarified that her results were not due to Ozempic, another GLP-1 receptor agonist often discussed in popular media, but specifically to Mounjaro prescribed by her doctor.
Mohanraj said she had struggled with weight management for years and attributed some of these difficulties to polycystic ovary syndrome (PCOS) and hypothyroidism, conditions known to affect metabolism and insulin sensitivity. She also noted a family history of similar endocrine issues, which she described as a genetic predisposition.
Her initial treatment included thyroid medication and birth control pills for PCOS. She later discontinued the contraceptive pills due to mood-related side effects and was started on metformin after investigations showed insulin resistance.
During this period, she also disclosed a diagnosis of clinical depression, which she said affected her motivation and lifestyle. She described stepping back from social media due to body image concerns.
Before starting medication, Mohanraj attempted structured diet plans, daily exercise, increased water intake, higher protein consumption, and maintaining roughly 10,000 steps per day, even on rest days. Although she noticed a reduction in body measurements, her overall weight remained largely unchanged.
She later developed plantar fasciitis and elevated uric acid levels. On medical advice, she paused physical training. She said some of the inches she had lost returned during this period, which she found discouraging.
Aishwarya Mohanraj said she began Mounjaro on May 1, 2025, after reviewing her blood reports with her doctor. She described Mounjaro as a weekly injectable medication used for type 2 diabetes management and chronic weight management.
She reported losing about 1 kg in the first week and approximately 4 kg in the first month. Over six months, her weight declined from 74 kg to 52 kg, reflecting her personal tirzepatide weight loss results.
She also described changes during treatment. Her menstrual cycles became regular after starting Mounjaro, which she linked to improved insulin resistance. She experienced intense nausea during the first month, which later subsided, although her appetite remained markedly reduced. She also reported significant hair fall, which she associated with rapid weight loss.
Clinically, diffuse hair shedding after rapid weight change is commonly seen as telogen effluvium, a temporary condition triggered by physiological stress or significant weight reduction.¹
Tirzepatide and GLP-1 therapies often have these common side effects:
Nausea and gastrointestinal discomfort, particularly in early weeks
Marked appetite suppression
Fatigue or headache in some individuals
Hair shedding related to rapid weight loss (telogen effluvium)
Potential nutritional shifts during rapid weight reduction, which clinicians often monitor
Large clinical trials of tirzepatide have similarly reported gastrointestinal symptoms as the most frequent adverse effects.²
Aishwarya Mohanraj said each injection cost her around 4,000 euros in her treatment setting, with costs rising as dosage increased.
In India, Mounjaro (tirzepatide) has been approved by the Central Drugs Standard Control Organisation and is now available by prescription for type 2 diabetes and chronic weight management. It is marketed in vial and prefilled pen (KwikPen) formats.
Reported pricing in India begins at approximately ₹3,500 for a 2.5 mg vial and about ₹4,375 for a 5 mg vial, with higher doses and KwikPen formats costing more. Monthly treatment expenses vary substantially depending on dose, formulation, and location.
As with other GLP-1 weight loss injections, tirzepatide remains a prescription-only medication that should be initiated and monitored by qualified clinicians, typically endocrinologists or diabetologists. Patients are advised to discuss suitability, side effects, and financial implications before starting therapy.
Aishwarya Mohanraj emphasized that she is not qualified to provide medical advice and repeatedly urged viewers not to use the drug without professional guidance.
She explained that she chose to speak publicly because she had documented her fitness journey online and later appeared visibly thinner, prompting questions from followers. She said she felt responsible for clarifying that medication played a major role rather than diet and exercise alone.
She also acknowledged delaying her disclosure due to fear of online scrutiny and uncertainty about how her body would respond to treatment. She said she decided to share her experience only after completing most of the course and feeling more confident about the outcome.
What is Mounjaro?
Mounjaro is a prescription injectable medication containing tirzepatide, a dual GIP and GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
Is Mounjaro approved for weight loss?
In many countries, including India, tirzepatide is approved for diabetes and chronic weight management under medical supervision.
What are common Mounjaro side effects?
Nausea, appetite suppression, gastrointestinal discomfort, fatigue, and hair shedding related to rapid weight loss are among the most commonly reported effects.¹ ²
Can Mounjaro help with PCOS-related weight challenges?
By improving insulin resistance, tirzepatide may support weight management in some people with PCOS, but responses vary widely and treatment should always be guided by a specialist.
References:
Harrison, Sharon, and Wilma Bergfeld. 2009. “Diffuse Hair Loss: Its Triggers and Management.” Cleveland Clinic Journal of Medicine 76 (6): 361 to 367. https://www.ccjm.org/content/76/6/361
Jastreboff, Ania M., et al. 2022. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine 387 (3): 205 to 216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038